Author(s): Bunte MC, Infante de Oliveira E, Shishehbor MH
Abstract Share this page
Abstract The treatment of resistant hypertension has undergone remarkable advancements in recent years. Endovascular radio frequency renal sympathetic denervation (RSD) has shown initial success in treating resistant hypertension by targeting the connection between the brain and renal sympathetic nerves. However, the encouraging results of first-generation RSD have been tempered by important procedural limitations and a need for long-term results of safety and efficacy. In an effort to build on early clinical success, several second-generation RSD technologies are now being developed that may improve procedural safety and efficacy. Preliminary evidence for some of the latest technologies is now available. In this review, we summarize the current evidence in support of RSD and consider unique features of several new technologies that are likely to refine the endovascular treatment of resistant hypertension. Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
This article was published in JACC Cardiovasc Interv
and referenced in Medicinal chemistry